Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2074 in advanced solid tumors
NCT05646797Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of ASP2074 in colorectal adenocarcinoma, pancreatic adenocarcinoma (PDAC), esophageal adenocarcinoma (EAC) and 2 more (4 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events at 15 months and 4 more. Started Feb 2023; status: terminated.
02
Drugs
ASP2074
03
Conditions
colorectal adenocarcinomapancreatic adenocarcinoma (PDAC)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on NCT05646797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646797.